Pacira Pharma (PCRX) Tops Q3 EPS by 17c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'
November 9, 2017 9:56 AM ESTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $39.00 (from $38.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.
Analyst Gary Nachman notes a positive outlook on the shares, as the company reported earnings per share... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies
November 9, 2017 8:29 AM ESTJefferies lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $52.00 (from $57.00) while maintaining a Buy rating following results.
Analyst David Steinberg trimmed FY17 Exparel revs by $8M to $283M to align with the midpoint of updated guidance.They also trim FY18-20 sales ests by 4-6%
... More